Fig. 1: FimH promotes the activation of DCs in inguinal lymph nodes (iLN) in mice in vivo.
From: Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy
C57BL/6 mice were injected subcutaneously (s.c.) with 2.5 mg per kg of FimH and 1 mg per kg of LPS for 24 h, and the inguinal lymph nodes (iLN) were harvested. a The expression levels of costimulatory molecules and MHC classes I and II in CD8α+ DCs (upper panel) and CD8α− DCs (lower panel) are shown. (n = 6 mice, one-way ANOVA, mean ± SEM). b Flow cytometry analysis of costimulatory molecules and MHC classes I and II in iLN DCs from toll-like receptor 2 (TLR2)- and TLR4-knockout (KO) mice. (n = 6 mice, two-way ANOVA, mean ± SEM). c Serum concentrations of IL-6, IL-12p40, and TNF-α in wild type, TLR2-KO and TLR4-KO mice are shown. (n = 6 mice, two-way ANOVA, mean ± SEM). d Mean values of the mRNA expression levels in the iLN are shown. (n = 6 mice, two-way ANOVA, mean ± SEM).
